Custom synthesis outperforms; generics vertical underperforms

Company
11 Nov 2024
5 Min read 
  • Divis Laboratories 2QFY25 Results Update in Healthcare sector
  •  Financials & Valuation: Sales, EBITDA, Adj. PAT, Ratios, Valuations
  •  Shareholding pattern: Promoter, DII, FII, Others
  •  Divis Lab's performance in 2QFY25 and future outlook
  •  Management commentary on contrast media, peptides, and supply chain management
  •  Financials and valuations: Income statement, balance sheet, ratios, cash flow statement
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority

Click here to see your activities